ABOUT MYCAPSSA

The first and only FDA-approved oral somatostatin analog (SSA)

Consistent Control for Patients with Acromegaly with Daily Oral MYCAPSSA

MYCAPSSA maintained normal IGF-I levels in most patients who switched from iSSAs^1,2

In the Pivotal Phase 3 Trial, 58% of patients and 19% of the placebo group maintained biochemical control

Twice-daily MYCAPSSA provides consistent hormonal control^1,2

MYCAPSSA was generally well-tolerated in clinical trials^1-3

MYCAPSSA can cause problems with the gallbladder. Blood sugar, thyroid levels, and vitamin B12 levels may be impacted

Amryt Assist offers personalized and comprehensive support to help you and your patients with starting and staying on MYCAPSSA

Interested in learning more?

Let us know how we can help:

I'd like to request a visit or schedule a conversation with an Amryt Rare Disease Specialist.

I'd like to receive additional information and resources for MYCAPSSA.

# of patients with acromegaly*

# of acromegaly patients managed*

*Required Field

By clicking 'Submit', I agree to receive communications from Amryt Pharmaceuticals, Inc., and I understand that my information will be used in accordance with the Amryt Pharmaceuticals, Inc. Privacy Policy.

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION AND USAGE
MYCAPSSA (octreotide) delayed-release capsules, for oral use, is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.

CONTRAINDICATIONS
Hypersensitivity to octreotide or any of the components of MYCAPSSA. Anaphylactoid reactions, including anaphylactic shock, have been reported in patients receiving octreotide.

WARNINGS AND PRECAUTIONS
MYCAPSSA can cause problems with the gallbladder. Monitor patients periodically. Discontinue if complications of cholelithiasis are suspected.

Blood sugar, thyroid levels, and vitamin B₁₂levels should be monitored and treated accordingly.

Bradycardia, arrhythmia, or conduction abnormalities may occur. Treatment with drugs that have bradycardia effects may need to be adjusted.

ADVERSE REACTIONS
The most common adverse reactions (incidence >10%) are nausea, diarrhea, headache, arthralgia, asthenia, hyperhidrosis, peripheral swelling, blood glucose increased, vomiting, abdominal discomfort, dyspepsia, sinusitis, and osteoarthritis.

DRUG INTERACTIONS
The following drugs require monitoring and possible dose adjustment when used with MYCAPSSA: cyclosporine, insulin, antidiabetic drugs, calcium channel blockers, beta blockers, lisinopril, digoxin, bromocriptine, and drugs mainly metabolized by CYP3A4. Counsel women taking an oral contraceptive to use an alternative non-hormonal method of contraception or a back-up method when taking MYCAPSSA.

Patients taking proton pump inhibitors, H2-receptor antagonists, or antacids concomitantly with MYCAPSSA may require increased dosages of MYCAPSSA.

PREGNANCY
Advise premenopausal females of the potential for an unintended pregnancy.

To report SUSPECTED ADVERSE REACTIONS, contact the product information department at 1-844-312-2462 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch